

<u>MA (EU) number</u>	<u>(Invented) name</u>	<u>Strength</u>	<u>Pharmaceutical Form</u>	<u>Route of Administration</u>	<u>Immediate Packaging</u>	<u>Pack size</u>
EU/1/10/614/002	Menveo	-- <sup>1</sup>	Powder and solution for solution for injection	Intramuscular use	MenA lyophilised conjugate component: vial (glass); MenCWY liquid conjugate component: vial (glass)	5 vials + 5 vials
EU/1/10/614/003	Menveo	-- <sup>1</sup>	Powder and solution for solution for injection	Intramuscular use	MenA lyophilised conjugate component: vial (glass); MenCWY liquid conjugate component: vial (glass)	1 vial + 1 vial
EU/1/10/614/004	Menveo	-- <sup>1</sup>	Powder and solution for solution for injection	Intramuscular use	MenA lyophilised conjugate component: vial (glass); MenCWY liquid conjugate component: vial (glass)	10 vials + 10 vials

--<sup>1</sup> Meningococcal group A oligosaccharide 10 micrograms conjugated to Corynebacterium diphtheriae CRM197 protein 16.7 to 33.3 micrograms/0.5 ml  
Meningococcal group C oligosaccharide 5 micrograms conjugated to Corynebacterium diphtheriae CRM197 protein 7.1 to 12.5 micrograms/0.5 ml  
Meningococcal group W135 oligosaccharide 5 micrograms conjugated to Corynebacterium diphtheriae CRM197 protein 3.3 to 8.3 micrograms/0.5 ml  
Meningococcal group Y oligosaccharide 5 micrograms conjugated to Corynebacterium diphtheriae CRM197 protein 5.6 to 10.0 micrograms/0.5 ml